medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Determination of vancomycin pharmacokinetic/pharmacodynamic target and individualized dosing regimen recommendation in ICU neonates

Zhe Tang,[a] Wei-wei Shuai,[a] Jing-jing Li,[c] Yan-xia Yu,[c] Miao Qian,[b] Xin Tong,[a] Jing Cao,[a]# Zheng Jiao [d]#

[a]Department of Pharmacy, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China

[b]Department of Neonatology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China

[c]Department of Pharmacy, Suzhou Municipal Hospital, Suzhou, China

[d]Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

Running Head: PK/PD target of vancomycin in ICU neonates

#Correspondence

Zheng Jiao, jiaozhen@online.sh.cn

Jing Cao, njfycj@163.com.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

ABSTRACT

A Bayesian-derived area-under-the-curve from 0 to 24 h to minimum inhibitory concentration (AUC_{24}/MIC) of 400 to 600 has been recommended as the pharmacokinetic/pharmacodynamic (PK/PD) target of vancomycin (VAN) treatment in adults. However, limited data exists in neonates to support this target. Therefore, this study aimed: (i) to develop a population PK model to characterize significant covariates and to estimate AUC; (ii) to determine the neonatal PK/PD target of VAN and potential influence factors on this target; (iii) to design neonatal VAN recommendation based on the evaluated target. A single center retrospective observational cohort study was conducted. A population PK model was established by using Monolix 2019R2. Acute kidney injury (AKI) for all 182 patients were screened to determine the upper limit of VAN exposure. Clinical efficacy of 42 patients with blood culture proved staphylococcal sepsis was analyzed, and the threshold in predicting efficacy was developed as the lower limit of exposure. AUC_{24} $\geqslant$ 623 (mg·h)/liter and concomitant use of VAS were independent risks for AKI. When adjusted by current body weight (cWT) $<$ 1.3 kg, AUC_{24}/MIC $<$ 242 was highly correlated with treatment failure. AUC_{24}/MIC of 250 to 600 with MIC assumed to 1 mg/liter was set as the optimal PK/PD target in neonates then dosing recommendation was designed. In conclusion, AUC_{24}/MIC is a good predictor for VAN toxicity and efficacy in neonates. The designed regimens are valuable for neonatal individualized dosing in ICU setting. (This study has been registered at chictr.org.cn under identifier ChiCTR1900027919.)

Key words: vancomycin, neonate, PK/PD, population PK modeling, AKI, efficacy

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION

Neonates are predisposed to late-onset neonatal sepsis (LOS) owing to their compromised immune function and medical interventions. *Staphylococcus aureus* and *other Staphylococcus spp.* are predominant pathogens leading to LOS. VAN, a glycopeptide antibiotic developed many years ago, remains the agent of choice against staphylococcal sepsis for patients in neonatal intensive care units (NICU) (1).

AUC_{24}/MIC has been identified as the most predictive PK/PD index of VAN treatment (2). Trough-based target is no longer recommended due to studies of efficacy and nephrotoxicity (3). Moreover, this target is regarded unreliable because of its interval-dependent nature (4, 5). American Society of Health-System Pharmacists (ASHP) has advocated a Bayesian-derived AUC/MIC ratio of 400 to 600 (assuming MIC of 1 mg/liter) as the target for adults infected by methicillin-resistant *S. aureus* (MRSA) (3). However, there is paucity of evidence in literature to guide the optimal exposure target in neonates.

VAN is a well-kwon potential renal toxic agent, while the breakpoint of its exposure in predicting AKI, to our knowledge, has not been reported in neonates. AUC $>$ 800 (mg·h)/liter was considered associated with the increased risk of nephrotoxicity in children (6). This target was often used as the upper limit of VAN exposure to design dosing regimen in neonates without solid validation in clinical studies (7). Additional risk of unnecessary overexposure maybe arises in this condition.

Controversies remain in VAN exposure required for clinical efficacy. AUC/MIC $>$ 400 was reported not related to improved outcomes and a relationship between AUC/MIC and

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

treatment failure failed to be established in pediatrics as well (8). Whether AUC/MIC > 400 is a necessary exposure for neonates is urgent to be verified.

Therefore, this study aimed: (i) to develop a population PK model to characterize significant covariates and to estimate AUC; (ii) to determine the neonatal PK/PD target of VAN and potential influence factors on this target; (iii) to design neonatal VAN recommendation based on the evaluated target to facilitate individualized dosing in regular NICU practice.

RESULTS

Study population

There were 185 neonates administered by intermittent intravenous infusion of VAN under therapeutic drug monitoring (TDM) in NICU of Nanjing Maternity and Child Health Care Hospital from 1st January 2016 to 31st December 2019. One hundred and eighty-two patients were eligible for this study with 286 trough and 125 peak concentrations monitored within the calibration range of analytical instrument. Two patients with incomplete clinical data and the sole patient suffered from hematological malignancy were excluded. The study flow was presented in Fig. 1.

All of patients were diagnosed as neonatal sepsis by clinical physicians with empirical VAN application. About half of patients were co-medicated meropenem (MEM) and 36 individuals were received vasoactive drugs (VAS). The major comorbidities comprised patent ductus arteriosus (PDA), pneumonia, bronchopulmonary dysplasia (BDP),

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

meningitis, neonatal necrotic enterocolitis (NEC) and persistent pulmonary hypertension of newborn (PPHN). The mortality of the whole population was 15 (8.24%).

Population PK modeling

A population PK model was developed to estimate PK parameters of patients. One compartment model with first-order elimination was enough to fit the data set. A proportional model was chosen as the residual model. Various models, including base model (Model I), simple exponent model (Model II), sigmoid function model (Model III), age-dependent exponent (ADE) model (Model IV) and body weight-dependent exponent (BDE) model (Model V), were investigated to screen the covariates of body size (9). The detailed process was summarized in Table S1.

Postmenstrual age (PMA) appeared to reflect VAN clearance (CL) variability better than gestational age (GA) or postnatal age (PNA) alone. The performance of sigmoid function (Model III) was not superior to the simple exponent function (Model II) with time-varying cWT and PMA, and ADE and BDE models (Model IV and V) seemed ill-conditioning and overparameterized. Therefore, Model II was selected for further analysis due to the lower Akaike information criteria (AIC) and Bayesian information criteria (BIC) compared to other ones.

Serum creatinine (SCR), creatinine clearance (CLCR), and co-administration of VAS were recognized as significant covariates on CL. Since SCR and CLCR were apparently correlated with each other and were almost equally-performed, SCR was retained on account of better accessibility in clinic. CL showed a 14% decrease with co-medicating

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

VAS. Moreover, cWT was added to volume of distribution (V) for physiologic plausibility (equation 1), and CL was illustrated in equation 2.

$$V = V_{pop} \times \left(\frac{cWT}{1.5}\right) \quad (1)$$

$$CL = CL_{pop} \times \left(\frac{cWT}{1.5}\right)^{0.75} \times \left(\frac{PMA}{32}\right)^{beta1} \times \left(\frac{30}{SCR}\right)^{beta2} \times F_{VAS} \quad (2)$$

Where V is volume of distribution of VAN, V_{pop} is the population estimate of V, cWT is the current body weight, CL is clearance, CL_{pop} is population estimate of CL, PMA is postmenstrual age, SCR is serum creatinine, and F_{VAS} is the scaling factor for co-medication of VAS.

Goodness-of-fit plots for the base model and final model were illustrated in Fig. 2. In contrast to the base model, plot of the final model showed no obvious bias or trend and much improved. The plots of normalized prediction distribution error (NPDE) were presented in Fig. S1. The histogram and probability density plot met the normality well, indicating a good fit of the model to individual data (Fig. S1). In the bootstrap process of 2000 time runs, the median parameter estimates were close to the final model (Table S2). 99% runs were successful, and bias in fixed effects were less than 5%, indicating that the final model was stable and able to redetermine the estimates of population PK parameters.

Twenty-eight patients from Li's study were included for external evaluation of the established model (10). In this data set, all the observations collected were troughs. The medians of cWT, PMA, and SCR were 1.66 kg (range, 0.80 to 2.52 kg), 33.22 weeks (range, 28.28 to 36.71 wk), and 35.42 μmol/liter (range, 14.17 to 51.71 μmol/liter) respectively. No patient was co-administered VAS. Mean prediction error (MPE) and mean absolute

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

prediction error (MAPE) of the final model was 3.97% (SD, 19.88%) and 13.01% (SD, 15.36%) respectively.

Since the external showed no obvious bias of the established model, we combined all the data and re-estimate the PK parameters. The estimates of the PK parameters did not show an apparent difference (Table 1).

Determination of the PK/PD target

(i) AKI analysis. AKI occurrence was screened for all the patients (Fig. 1). Generally, most of patients were not prescribed renal toxic agents besides VAN. VAS was the major nephrotoxin with the prescription for 36 individuals. Other typical renal toxic agents, like furosemide and ibuprofen, were applied for 30 and 8 patients respectively.

Seven patients were observed AKI during VAN treatment. Once AKI discovered, VAN dosage adjustments were executed by physicians immediately. Except 2 deaths, renal function of 5 survivals with initial impairment recovered as a lag decrease of SCR within 5 days of therapy.

Not unexpectedly, AKI patients had suppressed renal function with abnormally higher SCR, lower CLCR and VAN CL. AUC_{24} of them were dramatically elevated though there was no statistical difference in daily dose between AKI and non-AKI individuals (Table 2, Fig. 3). Most other characteristics were generally similar. In contrast to non-AKI patients, AKI patients were more likely to be prescribed by MEM, VAS, and furosemide. AKI patients also had a smaller PNA and a higher morbidity of PDA (Table 2).

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

AUC_{24} was confirmed strongly correlated with AKI in univariate logistic regression (ULR) ($P<0.01$) (Table 3). AUC_{24} of 623 (mg·h)/liter was detected as the threshold for AKI of by ROC analysis (Table 3, Fig. 4). This indicated AUC_{24} was a good predictor for AKI occurrence. PNA, PPHN, and concomitant use of VAS or furosemide were found as potential influence factors of AKI besides AUC_{24} (Table S3). Significant correlation between AUC_{24} and C_{min} (trough concentration) was identified (Spearman coefficient = 0.88, $P < 0.01$). Therefore, C_{min} was not included for further analysis. SCR and CLCR were also excluded because they were diagnostic criteria of AKI. In multivariate logistic regression (MLR), independent predictors of AKI included $AUC_{24} \geqslant 623$ (mg·h)/liter and concomitant use of VAS (Table 4).

(ii) Efficacy analysis. Seventy-nine patients had positive blood culture results among the whole population. Thirty-one patients with blood culture proved non-staphylococcal sepsis, 4 patients with polymicrobial infections, and 2 patients co-administered anti-infective sensitive to the identified staphylococcus were excluded. Finally, 42 individuals with blood culture proved staphylococcal sepsis were eligible for efficacy analysis (Fig. 1). Sixteen individuals of them infected by *S. aureus*, and others by *other Staphylococcus spp.*

Seven patients experienced treatment failure. Three were dead during VAN therapy and 4 were observed with positive blood culture at ≥ 5 days after VAN started. Linezolid (LZD) therapies were then applied as an alternative for them with satisfied clinical outcomes. None with recurrence of bacteremia was observed during their hospital stay.

Most patients with ineffective treatment were very-low-birth-weight (VLBW) ones compared to effective patients including both low-birth-weight (LBW) and normal-birth-

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

weight (NBW) individuals. Mortality of ineffective individuals was also higher, while all effective members were survived. Despite insignificant difference in daily dosage and MICs, AUC_{24}/MIC were much lower among ineffective ones. (Table 2, Fig. 3).

AUC_{24}/MIC was found marginally significantly correlated with clinical efficacy ($P < 0.1$) (Table 3). The threshold for efficacy identified by ROC curve was AUC_{24}/MIC of 242 (Table 3, Fig. 4). In ULR, bWT (birth weight) and cWT, two variables highly correlated, seemed strongly associated with efficacy ($P < 0.05$) (Table S3). cWT was included in MLR since it better reflected the actual physiological status when VAM was applied. Results of MLR revealed that cWT $<$ 1.3 kg and AUC_{24}/MIC $<$ 242 were significant risk factors of treatment failure.

Dosing regimen design

On the basis of statistical analysis above, VAN PK/PD target in neonates was set as AUC_{24}/MIC of 250 to 600 with MIC assumed to 1 mg/liter. The dosage regimens recommended by current references and this study were displayed in Table 5 and Table 6 respectively (11, 12).

According to results in Table 6, patients with concomitant use of VAS were required a reduced daily dose. In general, dosing interval of 18 to 24 h was suitable for extremely preterm patients (PMA $<$ 28 wk) with single dosage of 10 to 20 mg/kg. For preterm ones with PMA of 28 to 36 wk, proper dosing intervals varied from 12 to 18 h. It was enough for term neonates with interval of 8 to 12 h. Interval shorter than 8 h seemed unnecessary.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Our results suggested daily dose of extremely-low-birth-weight (ELBW) neonates with birth weight ＜ 1 kg was 12.5 to 23 mg/kg. However, Neonatal Formulary recommended a daily dose of 20 mg/kg for all ELBW neonates and the maximum daily dose of Red Book for these patients was 30 mg/kg. Quite a number of ELBW neonates were obviously overdosed in these references (Table 5). Table 6 also showed a daily dose of 20 to 52.5 mg/kg was required for NBW neonates with birth weight ＞ 2.7 kg and SCR ≤ 60 μ mol/liter. While Red Book claimed a daily dose of 30 mg/kg for patients (GA ＞ 28 wk) with normal renal function (SCR < 61.7 μ mol/liter) (Table 5). It was apparent that this regimen was unable to satisfy the treatment need of large proportional NBW neonates.

DISCUSSION

AUC_{24}/MIC of 400 to 600 has been identified as the recommended PK/PD target in adults while few studies incorporating population PK modeling were conducted to determine or verify PK/PD target for VAN treatment in neonates (2, 3). In our study, a Bayesian-derived target of AUC_{24}/MIC 250 to 600 has been established in neonatal population for the first time and applied to design individualized dosing regimen.

In order to ensure the accuracy of PK parameter estimation, a population PK model has been developed and evaluated. The clearance of a typical patient with cWT of 1.5 kg, PMA of 32 weeks, SCR of 30 μmol/liter, and without VAS co-medication is estimated to 0.06 liter/(h·kg). This value is consistent with the range of 0.04 to 0.10 liter/(h·kg) from previous VAN population PK reports in neonates, and no obvious ethnic difference is observed (10,

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

13-20). The results of external evaluation also confirm that the predictive ability is satisfying.

The recommended PK/PD target in adults is determined by AUC_{24} estimated using validated Bayesian method and MICs obtained by broth microdilution method (BMD) approach (3). Achievement of our target complies with exactly the same method. This allows us to compare these two targets obtained from different populations directly. It is noticed that the lower limit of target for neonates is relatively lower (AUC/MIC of 250 vs. 400) and two target ranges are overlapped in some extent. The threshold in predicting VAN efficacy is obtained on the basis of staphylococcal sepsis in this study, while VAN treatment in neonates with staphylococcal infections is rarely reported to fail (3). It is reasonable that a lower AUC_{24}/MIC ratio target is also possible to be effective for neonates with staphylococcal LOS.

Our population PK model has identified VAS as an indicator of decreased VAN CL. The application of VAS for ICU neonates has also been reported as an independent risk factor for development of AKI (21). In our study, 85.7% (6/7) patients with AKI were co-mediated with VAS. Zhao's study regards VAS as an indirect surrogate for the severity of illness on account of its application often accompanied by decreased blood pressure and hypoperfusion (22). AKI may be induced in such a pathophysiological condition.

Whether VAN has a direct renal toxic effect or whether high exposure is a consequence of renal impairment is still under debate (23). Previous report illustrates that VAN-induced nephrotoxicity does not exist alone but occurs when other nephrotoxins are co-administered (6, 23), and the major nephrotoxin in our institution is VAS. Results of MLR

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

shows high VAN exposure of $AUC_{24} \geqslant 623$ (mg·h)/liter remains an independent predictor of AKI after adjustment of concomitant use of VAS. Although our study cannot explain whether the threshold for AKI will be varied by concomitant use of VAS, there is a reason to believe both high VAN exposure and VAS application probably co-contribute the development of AKI.

Seven (4%) cases of VAN-induced AKI were observed in this study within the range of 1 to 9% as former report (24). Except 2 deaths, renal functions of survivals were recovered to normal level with the progress of treatment although VAN exposures were abnormally high in a short period. The VAN dosage of them was kept monitoring and adjusted based on TDM results. All survivals were recovered without other obvious ADRs during their hospital stay. This finding agrees with the previous report in children (25). It indicates that neonates may be relatively tolerant to high VAN exposure and renal impairments for them are reversible. The ongoing monitoring of both VAN concentrations and SCR needs to be emphasized during the treatment to ensure the discovery of AKI without delay and avoid possible serious ADRs.

In the efficacy analysis, when adjusted by cWT < 1.3 kg, a clear association between AUC_{24}/MIC < 242 and VAN treatment failure has been verified. Low-weight neonates, especially individual weighted less than 1.5 kg, often means growth defects, higher mortality and more morbidities (26). It is reasonable that low-weight neonates are more likely to experience treatment failures.

The relationship between VAN exposure and clinical efficacy failed to establish in past pediatric and neonatal studies (8, 27). The possible reasons for this disparity may be caused

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

by following points. Primarily, previous studies contain patients with various infection sites while all patients in our study have bloodstream infection (8, 27). Considering several breakpoints reported by studies on different infectious diseases in adults, the threshold of AUC/MIC may be varied by different infection sites (28-30). Secondly, the whole population in previous studies are under a relatively low VAN exposure (8, 27). The correlation between efficacy and AUC_{24}/MIC ratio may not possible to be established due to AUC_{24}/MIC ratios concentrated within a narrow range. The comparison of characteristics of effective and ineffective patients reflects that main reason for treatment failure is still inadequate VAN exposure (AUC_{24}).

In contrast to our study, regimens in current references seems over-simplified. The scheme in Neonatal Formulary is merely PMA-based while regimen in Red Book is designed on the basis of GA and SCR (11, 12). According to our population PK model, renal function and concomitant use of VAS are significant covariates on VAN CL and unable to be out of consideration in regimen design. GA alone is not enough to describe the maturation of neonates and PMA is a better predictor for CL apparently. Overall, the current recommended regimens from Neonatal Formulary and Red Book are inappropriate and regimen designed in this study seemed more sophisticated and suitable for clinical practice.

There are several limitations in our study. First, PK/PD target found in this study gives no consideration of bacterial resistance which needs the support of further microbiological researches. Second, the sample size for the study is small especially for patients with AKI or ineffective treatment. Although this did not affect our ability to find statistical breakpoints in predicting AKI or VAN treatment failure, it is not a sufficiently robust

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

sample to support the established PK/PD target. Last but not the least, the retrospective nature of this study may lead to confounding and bias that may well be avoided with prospective study methods. Our findings need to be validated further in large multi-centered prospective studies.

CONCLUSION

In conclusion, AUC_{24}/MIC is a good predictor for VAN toxicity and efficacy in neonates. A Bayesian-derived AUC_{24}/MIC ratio of 250 to 600 is regarded as an appropriate PK/PD target of VAN treatment assumed MIC to 1 in ICU neonates balancing treatment achievement and AKI risks. AKI is more likely to occur when VAN is applied with concomitant use of VAS. Underdose of VAN and low-weight of neonates co-contribute to possible treatment failure. Individualized dosing regimens on the basis of the developed target are valuable for clinical practice.

METHODS

Study design

A single center retrospective observational cohort study was conducted at Nanjing Maternity and Child Health Care Hospital (Nanjing, China). The electronic medical records of all patients who accepted VAN therapy in NICU from 1st January 2016 to 31st December 2019 were reviewed to determine eligibility.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

This study was executed in accordance with the recommendations of the Declaration of Helsinki (2000). The protocol was approved by the Ethics Committee of Nanjing Maternity and Child Health Care Hospital. Identities of patients were hidden during the study. Informed consent was approved unnecessary due to retrospective nature of the study. This study was registered at chictr.org.cn under identifier ChiCTR1900027919.

Study population

Patients with postmenstrual age (PMA) ≤ 48 weeks when VAN began were included. All individuals were treated with VAN for at least three days and at least one serum concentration was monitored. The exclusion criteria were as follows: Complete data were unavailable; VAN serum concentrations were out of the calibration range of analytical devices.

Information of interest included: GA, PNA, PMA, bWT, cWT, dosing history, VAN serum concentration, SCR, CLCR calculated by Schwartz equation (31), co-medications (especially concomitant use of nephrotoxins like VAS, non-steroidal anti-inflammatory drugs, or loop diuretics), clinical diagnosis, radiographic examinations, laboratory tests and microbiology culture.

According to the local protocol, neonates with suspected or confirmed sepsis received empirical therapy with VAN in combination with MEM based on presumptive diagnosis. Once a diagnosis was established, anti-infectives were rationalized to cover the causative pathogen. Target trough levels of VAN according to local guidelines were 10 to 20 mg/liter (32). As this was an observational and respective study, dosage adjustment based on TDM results were determined at the discretion of treating physicians.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

VAN (Vancocin, Lilly, S.A, Suzhou, China) was administered 10~15 mg/kg per time from every 8 to 18 h with intermittent infusion lasting 60 min. Blood samples were monitored half an hour before the start of vancomycin (trough concentration) or half an hour after the completion of infusion (peak concentration). All the samples were collected prior to the fourth or fifth dose (steady state). If the dosage was changed, it recommended TDM until steady state was reached.

Analytical method

VAN concentrations were analyzed by fluorescence polarization immunoassay with an ARCHITECT i2000SR (Abbott Laboratories, Chicago, IL, USA) within 24 h after samples obtained. The limit of detection was 1 mg/liter, and the calibration range of this assay was 3 to 100 mg/liter. The intra-day and inter-day coefficients of variation (CV) were less than 20%. Any concentration out of calibration range were excluded from the study.

SCR samples were analyzed with enzymatic method by using Beckman Coulter AU5800 (Beckman Coulter Inc., Brea CA, USA). The calibration range was from 3 to 100 mg/liter. The intra-day and inter-day CVs were less than 3.75%.

Etiological examinations were provided by clinical laboratory of our hospital by using VITEK 2 microbial identification system (bioMérieux, Lyon, France). BMD method was used to determine MICs. The interpretative reports were issued by the laboratory technicians according to the criteria recommended by the Clinical Laboratory Standards Institute (CLSI).

Population PK modeling

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

A population PK model was conducted among all individuals in this study to calculate PK parameters precisely by using Monolix (version 2019R2, Lixoft, France). Stochastic Approximation Expectation Maximization (SAEM) algorithm was used to estimate PK parameters and their variability.

One or two compartment model with first-order elimination was tried to fit the dataset. The interindividual variability of the pharmacokinetic parameters was estimated by using an exponential model and was expressed as equation 3:

$$P_i = P_{pop} \times e^{\eta_i} \quad (3)$$

where P_{pop} is the population typical value of parameter, and P_i refers to parameter value of the ith subject with random variable η_i, which is assumed normally distributed with a mean of zero and variance of ω^2.

Residual unexplained variability was tested by an additive model, exponential model, or a combined additive and exponential model.

The potential covariates were investigated for their influence on PK parameters. Considering the rapid changing pathophysiological status of neonates, all the covariates were defined as time-varying ones (regressor in Monolix). Any categorical variable present in less than 20% of the population was not going to be tested.

Five models were employed to describe the impacts of size (weight) and maturation (age) on VAN CL (33). The performance of model fitting was investigated in further analysis. Model I ~ III based on weight scaling of CL were tested using equation 4.

$$CL_i = CL_{pop} \times \left(\frac{WT}{WT_{median}}\right)^{k_1} \times MF \quad (4)$$

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

where CL_i is the typical clearance of ith individual, and CL_{pop} is population typical value of VAN clearance. WT is the weight of ith individual and WT_{median} is median weight of the population. k_1 is the exponent. MF represents the maturation factor (MF) which defines the maturing process. It is set to 1 for all the models except Model III.

Model I: in the base model, the exponent k_1 is fixed to 0.75 (34).

Model II: in the simple exponent model, the exponent k_1 is fixed to 0.75. Age (GA, PNA, and PMA) with exponential function is tested to explore the effect on VAN CL.

Model III: in the sigmoid maturation model, the exponent k_1 is fixed to 0.75 and MF is calculated according to equation 5 (34).

$$MF = \frac{1}{1+\left(\frac{Age}{MT_{50}}\right)^{\gamma}} \quad (5)$$

where MT_{50} is the value of age when maturation reaches 50 % of the adult clearance, and γ is the Hill coefficient which controls the slope of sigmoid function.

Model IV: the ADE model (equation 6) (9).

$$k_1 = k_0 - \frac{k_{max} \times Age^{\gamma}}{k_{50}^{\gamma} + Age^{\gamma}} \quad (6)$$

Model V: the BDE model (equation 7) (35).

$$k_1 = k_0 - \frac{k_{max} \times WT^{\gamma}}{k_{50}^{\gamma} + WT^{\gamma}} \quad (7)$$

where k_0 is the value of the exponent at birth (0 years) (Model IV) or at a theoretical weight of zero (Model V), k_{max} is the maximum decrease of the exponent, k_{50} is the age (Model

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

IV) or weight (Model V) at which a 50 % decrease in the maximum decrease is attained, and γ is the Hill coefficient used to determine the steepness of the sigmoid decline.

Structural models were regarded preferential due to lower AIC and BIC (36). The selection of covariates was determined using a forward selection process and a backward elimination process. Nested covariate models were statistically compared using a likelihood ratio test on the differences in the objective function value (OFV). A reduction in OFV of 3.84 ($p < 0.05$) for forward inclusion and an increase in OFV of 6.63 ($p < 0.01$) for backward elimination were the criteria for retaining a covariate in the model.

Both internal validation and external validation were performed to verify the predictive performance of the model. The final model was internally assessed by visual inspection of goodness-of-fit plots, normalized prediction distribution error (NPDE) and bootstrap (36-38). The NPDE distribution was expected to follow a normal distribution with a mean of 0 and a variance of 1. The bootstrap procedure was replicated 2000 runs with the R package Rsmlx (version 2.0.2, https://cran.r-project.org/web/packages/Rsmlx/index.html). The median values and 95% confidence intervals of PK parameters were compared with estimates from the final model. Bias in fixed effects less than 5% was thought acceptable. Bias (%) was calculated by equation 8:

$$Bias\ (\%) = \frac{Bootsrap\ median - final\ model\ estimate}{final\ model\ estimate} \times 100\% \quad (8)$$

The external data set of neonates from Li's research was used to validate the final model (10). MAPE and MPE were applied to calculate bias and imprecision of predictive performance (equation 9 and 10) (39). MAPE and MPE values within the range of 30% and 20% respectively were considered acceptable for the final model.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

$$MAPE(\%) = \frac{1}{N}\sum\left|\frac{IPRED_i - OBS_i}{OBS_i}\right| \quad (9)$$

$$MPE(\%) = \frac{1}{N}\sum\frac{IPRED_i - OBS_i}{OBS_i} \quad (10)$$

where $IPRED_i$ and OBS_i is individual prediction and the observation of the ith subject, and N is the number of subjects in the data set for external evaluation.

Determination of the PK/PD target

(i) AKI analysis. AKI occurrence of all the patients were screened. The association between VAN exposure and AKI occurrence was investigated and the breakpoint in predicting AKI was tried to discover as the upper limit of VAN exposure. AKI definition for neonates were: an increase of SCR by 26.5 μmol/liter within 48 h, or a SCR rise to ⩾ 1.5 times from the baseline within 7 days, or a urine volume <0.5 ml/(kg·h) for 6 hours (40). AUC_{24} was calculated by equation 11.

$$AUC_{24} = \frac{Daily\ dose}{CL} \quad (11)$$

Where AUC_{24} is the Bayesian-derived area-under-the-curve from 0 to 24 h, and CL is VAN clearance.

(ii) Efficacy analysis. Patients with blood culture proved staphylococcal sepsis were assessed the qualification of efficacy analysis. Patients with the following characteristics were excluded: length of VAN treatment less than 5 days, polymicrobial infection or concomitant antimicrobial agent sensitive to the identified staphylococcus.

The clinical efficacy of eligible patients was analyzed. The correlation between VAN steady exposure after dose adjustment and clinical efficacy was explored as well. The

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

breakpoint that provided the greatest difference in treatment failure was regarded as the lower limit of VAN exposure. VAN treatment failure was defined as positive blood culture at ⩾ 5 days after initiation of vancomycin treatment, recurrence of bacteremia within 30 days, or 30-day mortality (29, 30, 41).

Dosing regimen design

The PK model-based dosing recommendations were designed by using the optimal exposure target and were compared with current regimens in Neonatal Formulary and Red Book (11, 12).

Virtual patients with different physiological characteristics (i.e, different levels of ages, weights, or renal functions) were set for simulations. The PMA range of virtual patients was designated from 25 to 46 weeks. Their corresponding weights were medians obtained from the Fenton growth chart for neonates (42). 1000 replicates of each scenario were simulated by MC method to detect the most proper dosing scheme (43). R package mlxR (version 4.1.0, https://cran.r-project.org/web/packages/mlxR/index.html) was used to complete this procedure.

Statistical analysis

Baseline characteristics and PK/PD parameters of patients were summarized. Continuous variables were compared in Wilcoxon tests, and dichotomous variables in Fisher exact tests. Threshold values of VAN exposure in predicting AKI or efficacy were identified from Youden index (J) based on the receiver operating characteristic (ROC) analysis. J = maximum (sensitivity + specificity－1) (44).

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

ULR analyses were performed to test the correlation between variables and AKI occurrence or treatment failure. Potentially significant variables identified by ULR ($P < 0.2$) were included into MLR to identify predictors for AKI or efficacy (45). If variables were correlated, only one was included into the analysis. For variables exerting significant effects on AKI or efficacy, ROC analysis was employed to find cut-off values to create dichotomous variables for better professional explanation (46).

All statistical analyses were executed by R. $P < 0.05$ was considered as statistically significant. pROC package was used for ROC analysis (version 1.15.3, https://cran.r-project.org/web/packages/pROC/index.html).

DATA AVAILABILITY

The data of this study will be open to public through public access of ResMan (http://www.medresman.org.cn/pub/cn/proj/projectshshow.aspx?proj=1448) within 6 months after publication.

ACKNOWLEDGEMENTS

The authors would like to thank Dr Xiao-jun Ji (Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing, China) for his assistance with figure plotting.

FUNDING

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

This project was partly supported by the National Science Foundation for Young Scientists of China (No.) and Hospital Pharmacy Foundation of Nanjing Pharmaceutical Association (No. 2019YX004).

CONFLICTS OF INTEREST

All authors declare no conflicts of interest.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES

1. Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. 2013. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med 18:28-34.

2. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr., Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82-98.

3. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. 2020. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm doi:10.1093/ajhp/zxaa036.

4. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. 2011. Vancomycin: we can't get there from here. Clin Infect Dis 52:969-974.

5. Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M, Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y, Kimura T. 2013. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Journal of Infection and Chemotherapy 19:365-380.

6. Le J, Ny P, Capparelli E, Lane J, Ngu B, Muus R, Romanowski G, Vo T, Bradley J. 2015. Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children. J Pediatric Infect Dis Soc 4:e109-e116.

7. Dao K, Guidi M, Andre P, Giannoni E, Basterrechea S, Zhao W, Fuchs A, Pfister M, Buclin T, Csajka C. 2019. Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacol Res doi:10.1016/j.phrs.2019.104278:104278.

8. Hahn A, Frenck RW, Allen-Staat M, Zou Y, Vinks AA. 2015. Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia. Ther Drug Monit 37:619-625.

9. Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, Zhao Z, Miao L, Jiao Z. 2014. A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation. Clin Pharmacokinet 54:305-317.

10. Li JJ, Liu YX, Tang L, Weng XH, Wang SN, Jiao Z, Shang EN. 2017. Population Pharmacokinetics of Vancomycin in Chinese Neonates. Chin Pharm J 52:1434-1441.

11. Mills Q. 2014. Neonatal Formulary 7: Drug Use in Pregnancy and the First Year of Life, 7 ed. Wiley Blackwell. BMJ., UK.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

12. Pediatrics AAo, in Kimberlin DW, Brady MT, Jackson MA, (ed) LS. 2018. Red Book: Report of the Committee on Infectious Diseases, 31 ed. Itasca, IL: American Academy of Pediatrics, USA.

13. Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. 1994. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 56:169-175.

14. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. 2004. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother 48:1159-1167.

15. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NHG. 2007. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 63:75-84.

16. Lo YL, van Hasselt JG, Heng SC, Lim CT, Lee TC, Charles BG. 2010. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother 54:2626-2632.

17. Marques-Minana MR, Saadeddin A, Peris JE. 2010. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol 70:713-720.

18. Oudin C, Vialet R, Boulamery A, Martin C, Simon N. 2011. Vancomycin prescription in neonates and young infants: toward a simplified dosage. Arch Dis Child Fetal Neonatal Ed 96:F365-370.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

19. Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. 2012. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child 98:449-453.

20. Li ZL, Liu YX, Jiao Z, Qiu G, Huang JQ, Xiao YB, Wu SJ, Wang CY, Hu WJ, Sun HJ. 2018. Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates: Initial Dosage Recommendations. Front Pharmacol 9:603.

21. Stojanovic V, Barisic N, Milanovic B, Doronjski A. 2014. Acute kidney injury in preterm infants admitted to a neonatal intensive care unit. Pediatr Nephrol 29:2213-20.

22. Zhao W, Hill H, Le Guellec C, Neal T, Mahoney S, Paulus S, Castellan C, Kassai B, van den Anker JN, Kearns GL, Turner MA, Jacqz-Aigrain E, Consortium T. 2014. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. Antimicrob Agents Chemother 58:6572-6580.

23. Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. 2017. Establishment of an AUC 0–24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 61.

24. Lestner JM, Hill LF, Heath PT, Sharland M. 2016. Vancomycin toxicity in neonates: a review of the evidence. Curr Opin Infect Dis 29:237-247.

25. Le J, Vaida F, Nguyen E, Adler-Shohet FC, Romanowski G, Kim J, Vo T, Capparelli EV. 2014. Population-Based Pharmacokinetic Modeling of Vancomycin in Children with Renal Insufficiency. J Pharmacol Clin Toxicol 2:1017-1026.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

26. A. GC, E. JS. 2018. Avery's Diseases of the Newborn, 10 ed. Elsevier Inc, Philadelphia, PA.

27. Padari H, Oselin K, Tasa T, Metsvaht T, Loivukene K, Lutsar I. 2016. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? BMC Pediatr 16:206.

28. Gawronski KM, Goff DA, Jack B, Khadem TM, Bauer KA. 2013. A Stewardship Program's Retrospective Evaluation of Vancomycin AUC24/MIC and Time to Microbiological Clearance in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis. Clinical Therapeutics 35:772-779.

29. Jung Y, Song KH, Cho J, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD. 2014. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 43:179-183.

30. Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. 2015. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother 59:2978-2985.

31. Schwartz GJ, Brion LP, Spitzer A. 1987. The Use of Plasma Creatinine Concentration for Estimating Glomerular Filtration Rate in Infants, Children, and Adolescents. Pediatric Clinics of North America 34:571-590.

32. Ye Z-K, Chen Y-L, Chen K, Zhang X-L, Du G-H, He B, Li D-K, Liu Y-N, Yang K-H, Zhang Y-Y, Zhai S-D. 2016. Therapeutic drug monitoring of vancomycin: a

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Journal of Antimicrobial Chemotherapy 71:3020-3025.

33. Jacqz-Aigrain E, Leroux S, Zhao W, van den Anker JN, Sharland M. 2015. How to use vancomycin optimally in neonates: remaining questions. Expert Rev Clin Pharmacol 8:635-648.

34. Holford N, Heo YA, Anderson B. 2013. A pharmacokinetic standard for babies and adults. J Pharm Sci 102:2941-2952.

35. Wang C, Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Krekels EH, Tibboel D, Danhof M, Knibbe CA. 2012. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res 29:1570-1581.

36. Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, Dong J, Ruiz-Garcia A, Sweeney K, Cronenberger C. 2013. Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance. CPT Pharmacometrics Syst Pharmacol 2:e51.

37. Ette EI. 1997. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495.

38. Comets E, Brendel K, Mentré F. 2008. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R. Comput Methods Programs Biomed 90:154-166.

39. van der Meer AF MM, Touw DJ, Proost JH, Neef C. 2011. Optimal Sampling Strategy Development Methodology Using Maximum A Posteriori Bayesian Estimation. Ther Drug Monit 33:133-146.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

40. Khwaja A. 2012. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179-184.

41. Al-Sulaiti FK, Nader AM, Saad MO, Shaukat A, Parakadavathu R, Elzubair A, Al-Badriyeh D, Elewa H, Awaisu A. 2019. Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial. Eur J Drug Metab Pharmacokinet 44:639-652.

42. Fenton TR, Sauve RS. 2007. Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart. Eur J Clin Nutr 61:1380-5.

43. Trang M, Dudley MN, Bhavnani SM. 2017. Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection. Curr Opin Pharmacol 36:107-113.

44. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. 2011. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77.

45. Zhang Z. 2016. Model building strategy for logistic regression: purposeful selection. Ann Transl Med 4:111.

46. Zhou ZR, Wang WW, Li Y, Jin KR, Wang XY, Wang ZW, Chen YS, Wang SJ, Hu J, Zhang HN, Huang P, Zhao GZ, Chen XX, Li B, Zhang TS. 2019. In-depth mining of clinical data: the construction of clinical prediction model with R. Ann Transl Med 7:796.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

633 **FIGURES**



634

635 **FIG 1** Study flow

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



FIG 2 Goodness-of-fit plot.

(A) Population predictions vs. observations. (B) Individual predictions (IPRED) vs. observations. (C) The time vs. the individual weighted residual errors (IWRES). (D) Serum concentrations (Cc) vs. IWRES. The black solid lines are the reference lines, and yellow solid lines are the loess smooth lines.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



FIG 3 Boxplots of VAN exposure parameters.

(A) Boxplot of AUC_{24} and occurrence of AKI. (B) Boxplot of AUC_{24}/MIC and VAN efficacy. Bold lines mean medians and fine lines shows lower and upper quartiles. Black color stands for AKI patients and red color for non-AKI ones. Orange color represents effective individuals and blue color represents ineffective ones.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



FIG 4 ROC analysis.

(A) ROC curve in AKI analysis (B) ROC curve in efficacy analysis. AUC is area under the curve.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

TABLES

TABLE 1 Results of population PK modeling

Parameter[a]	Original data set		New data set[c]	
	Value	RSE (%)[b]	Value	RSE (%)
Fixed Effects				
V_{pop}, liter	0.86	3.02	0.86	3.85
CL_{pop}, liter/h	0.09	2.11	0.09	2.10
beta1	2.35	1.20	2.40	3.03
beta2	0.18	3.41	0.22	2.86
F_{VAS}	0.86	0.34	0.86	0.30
Standard Deviation of the Random Effects				
omega_V	0.11	24.20	0.15	21.40
omega_CL	0.24	6.85	0.23	6.79
Error Model Parameters				
b	0.21	4.82	0.21	5.04

[a]V_{pop}, population typical value of volume of distribution; Cl_{pop}, population typical value of VAN clearance; F_{VAS}. scaling factor of VAS co-medication; omega_V, standard deviation of random effects for volume of distribution; omega_CL, standard deviation of random effects for VAN clearance; b, residual error parameter.

[b]RSE, relative standard error.

[c]A new data set combines original data set and the data set of external validation.

674 **TABLE 2** Baseline demographic characteristics and PK parameters in AKI analysis and efficacy analysis.

Variable[a]	AKI analysis[b]			Efficacy analysis		
	Normal patients (N=175) median (range/proportion)	AKI patients (N=7) median (range/proportion)	P	Effective patients (N=35) median (range/proportion)	Ineffective patients (N=7) median (range/proportion)	P
Maturation						
Gender	98/77 (male/female)	4/3 (male/female)	1.00	18/17 (male/female)	5/2 (male/female)	0.43
GA, wk	30.43 (22.29~41.29)	33.86 (24.71~40.00)	0.20	31.00 (24.43~40.00)	29.71 (26.29~33.29)	0.32
PNA, wk	2.24 (0.28~12.62)	0.85 (0.57~3.71)	<0.05	2.57 (0.93~5.00)	2.57 (0.85~4.43)	1.00
PMA, wk	33.33 (22.60~46.25)	34.78 (28.29~40.71)	0.48	33.81 (26.50~41.04)	32.28 (27.00~35.28)	0.32
bWT, kg	1.35 (0.55~4.40)	1.74 (0.77~3.05)	0.43	1.37 (0.70~3.03)	0.95 (0.77~1.18)	< 0.01
cWT, kg	1.58 (0.57~5.63)	1.80 (1.20~3.02)	0.57	1.58 (0.78~3.05)	1.25 (0.76~1.56)	< 0.01
Renal Function						
SCR, μmol/liter	26.70 (3.90~77.50)	85.90 (22.10~107.10)	<0.01	24.60 (9.60~55.21)	22.80 (10.70~44.40)	0.79
CLCR, (ml/min)/1.73m^2	35.33 (9.69~142.18)	19.73 (9.09~39.51)	<0.01	37.40 (17.55~81.95)	36.71 (22.37~51.40)	0.60
PK Parameters						
Daily dose, mg/kg	30.00 (13.33~63.22)	28.80 (19.35~46.69)	0.33	29.11 (15.48~44.26)	28.32 (18.42~58.97)	0.38
CL, liter/(h·kg)	0.06 (0.02~0.16)	0.03 (0.03~0.05)	<0.01	0.06 (0.04 ~ 0.16)	0.06 (0.05 ~ 0.12)	0.97
C_{min}, mg/liter	12.38 (3.11~33.01)	23.10 (12.51~51.36)	<0.01	13.48 (3.39~18.96)	11.38 (7.50~12.76)	< 0.05
AUC_{24}, (mg·h)/liter	468.70 (203.30~1118.40)	772.00 (476.90~1385.80)	<0.01	471.60 (272.10~627.80)	440.90 (325.60~485.10)	< 0.1
MIC, mg/liter	/	/	/	2.0 (0.5~2.0)	2.0 (2.0~2.0)	0.12

AUC_{24}/MIC	/	/	/	256.40 (136.00~1030.30)	215.60 (162.80~242.50)	< 0.01
Comorbidities						
PDA	74 (42.3%)	7 (100.0%)	<0.01	10 (28.6%)	3 (42.9%)	0.66
Pneumonia	74 (42.3%)	4 (57.1%)	0.46	8 (22.9%)	3 (42.9%)	0.35
BDP	41 (23.4%)	2 (28.6%)	0.67	5 (14.3%)	2 (28.6%)	0.27
Meningitis	36 (20.6%)	1 (14.3%)	1.00	4 (11.4%)	0 (0.00%)	1.00
NEC	31 (17.7%)	2 (28.6%)	0.61	5 (14.3%)	0 (0.00%)	0.57
PPHN	14 (8.00%)	2 (28.6%)	0.12	2 (5.71%)	0 (0.00%)	1.00
Co-medication						
Meropenem	82 (46.9%)	7 (100.0%)	<0.01	11 (31.4%)	2 (28.6%)	1.00
VAS	30 (17.1%)	6 (85.7%)	<0.01	2 (5.71%)	1 (14.3%)	0.43
Furosemide	26 (14.9%)	4 (57.1%)	<0.05	1 (2.86%)	1 (14.3%)	0.31
Ibuprofen	8 (4.57%)	0 (0.00%)	1.00	1 (2.86%)	0 (0.00%)	1.00
Outcome						
Mortality	13 (7.43%)	2 (28.6%)	0.10	0 (0.00%)	3 (42.9%)	< 0.01

[a]GA, gestational age; PNA, postnatal age; PMA, postmenstrual age; bWT, birth weight; cWT, current body weight; SCR, serum creatinine; CLCR, creatinine clearance; CL, VAN clearance; Cmin, trough concentration; PDA, patent ductus arteriosus; BDP, bronchopulmonary dysplasia; NEC, neonatal necrotic enterocolitis; PPHN, persistent pulmonary hypertension of newborn; VAS, vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and norepinephrine in our institution.

[b]AKI, acute kidney injury.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

TABLE 3 Results of ULR and ROC analysis

Variable[a]	OR (P)[b]	AUC_{ROC} (95% CI)[c]	Cut-off	SP[d]	SE[e]
AKI analysis					
AUC_{24}, (mg·h)/liter	1.01 (< 0.01)	0.89 (0.77~1.00)	623	0.85	0.86
Efficacy analysis					
AUC_{24}/MIC	1.02 (< 0.1)	0.81 (0.67~0.95)	242	0.86	0.66

[a]AKI, acute kidney injury.

[b]OR, Odds ratio and corresponding P value for univariate logistic regression.

[c]AUC_{ROC}, area under curve for ROC curve.

[d]SP, specificity of ROC analysis.

[e]SE, sensitivity of ROC analysis.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

TABLE 4 Results of MRL

Variable[a]	OR[a] (95%CI)	P
AKI analysis		
AUC_{24}⩾623 (mg·h)/liter	31.15 (3.21~302.00)	<0.01
Concomitant use of VAS	28.67 (2.95~278.52)	<0.01
Efficacy analysis		
AUC_{24}/MIC＜242	0.09 (0.01~0.97)	<0.05
cWT＜1.3kg	0.11 (0.01~0.80)	<0.05

[a]AKI, acute kidney injury.

[b]OR, adjusted odds ratio.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

TABLE 5 Dose recommendations in current references

Reference	Age (wk) / SCR (μmol/liter)[a]	Dose recommendations[b]
Neonatal Formulary	PMA <29	20mg/kg,q24h
	PMA 30~33	20mg/kg,q18h
	PMA 34~37	20mg/kg,q12h
	PMA 38~44	15mg/kg,q8h
	PMA > 45	10mg/kg,q6h
Red Book	GA≤28	LD: 20mg/kg
	SCR <44.2	MD: 15mg/kg,q12h
	SCR 44.2~61.7	MD: 20mg/kg,q24h
	SCR 70.6~88.2	MD: 15mg/kg,q24h
	SCR 97.0~123.5	MD: 10mg/kg,q24h
	SCR >123.5	MD: 15mg/kg,q48h
	GA > 28	LD: 20mg/kg
	SCR <61.7	MD: 15mg/kg,q12h
	SCR 61.7~79.4	MD: 20mg/kg,q24h
	SCR 88.2~105.8	MD: 15mg/kg,q24h
	SCR 114.7~141.2	MD: 10mg/kg,q24h
	SCR >141.2	MD: 15mg/kg,q48h

[a]SCR, serum creatinine; PMA, postmenstrual age; GA, gestational age.

[b]LD, loading dose; MD, maintenance dose.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

721 **TABLE 6 Results of dosing regimen simulation**

cWT[a] (kg)	PMA[b] (wk)	SCR[c] (μmol/liter)	Patients without VAS[d]	Patients with VAS
0.7~0.99	25~27	10	15~17.5mg/kg, q18h	17.5~20mg/kg,q24h
		25	12.5~15mg/kg, q18h	15~17.5mg/kg, q24h
		45	12.5~15mg/kg, q18h	12.5~15mg/kg, q24h
		60	10~12.5mg/kg, q18h	12.5~15mg/kg, q24h
		90	10~12.5mg/kg, q18h	12.5~15mg/kg, q24h
1.0~1.69	28~31	10	12.5~15mg/kg, q12h	15~17.5mg/kg, q18h
		25	10~12.5mg/kg, q12h	12.5~15mg/kg, q18h
		45	15~17.5mg/kg, q18h	12.5~15mg/kg, q18h
		60	12.5~15mg/kg, q18h	10~12.5mg/kg, q18h
		90	12.5~15mg/kg, q18h	10~12.5mg/kg, q18h
1.7~2.69	32~36	10	15~17.5mg/kg, q12h	12.5~15mg/kg, q12h
		25	12.5~15mg/kg, q12h	10~12.5mg/kg, q12h
		45	10~12.5mg/kg, q12h	15~17.5mg/kg, q18h
		60	10~12.5mg/kg, q12h	12.5~15mg/kg, q18h
		90	10~12.5mg/kg, q12h	12.5~15mg/kg, q18h
2.7~3.69	37~41	10	12.5~15mg/kg, q8h	15~17.5mg/kg, q12h
		25	10~12.5mg/kg, q8h	12.5~15mg/kg, q12h
		45	15~17.5mg/kg, q12h	12.5~15mg/kg, q12h
		60	12.5~15mg/kg, q12h	10~12.5mg/kg, q12h
		90	12.5~15mg/kg, q12h	10~12.5mg/kg, q12h
3.7 ~ 4.6	42~46	10	15~17.5mg/kg, q8h	12.5~15mg/kg, q8h

medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20045971; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

25	12.5~15mg/kg, q8h	10~12.5mg/kg, q8h
45	10~12.5mg/kg, q8h	15~17.5mg/kg, q12h
60	10~12.5mg/kg, q8h	12.5~15mg/kg, q12h
90	10~12.5mg/kg, q8h	12.5~15mg/kg, q12h

[a]cWT, current body weight.

[b]PMA, postmenstrual age.

[c]SCR, serum creatinine.

[d]VAS, vasoactive drugs.